Project: Specification for Printability of Bioink
Type: Standards Advancement Project
Partners: ASTM International and The SCB Cell Therapy and Tissue Engineering Sector Working Groups
Bioprinting—a method that uses 3D printing techniques to synthesize living tissues—is a rapidly expanding field within regenerative medicine with the potential to accelerate the testing timeline for new biopharmaceuticals that can treat a variety of conditions. Bioinks are used in bioprinting to mimic the extracellular matrix that supports cells in three dimensions. As an emerging field with many different manufacturers and academic researchers independently developing products, there is a lack of standardization for bioink properties such as viscosity and concentration and for bioink printing parameters such as the distance between the nozzle and printing space. Standards in this area will allow product developers to more easily reproduce test results and control product quality.
SCB is coordinating the development of an ASTM documentary standard that will define the range of desirable properties of bioinks to facilitate advancements in bioprinting.
Anticipated Availability: Late 2020
Convening Experts: SCB assembled a team of experts to develop an initial draft of this standard. The draft was presented at the May 2019 ASTM International Committee F04 meeting (ASTM WK65680: New Test Methods for Printability of Bioinks and Biomaterial Inks) and is expected to open for ballot soon.
Assessing Bioink Equipment Standards: As a complement to these efforts, SCB is also working with the American Society of Mechanical Engineers (ASME) and the Institute of Electrical and Electronics Engineers (IEEE) to coordinate the development of potential standards around the validation of bioprinting equipment and the verification of its electrical components. SCB is currently looking for subject matter experts to provide input on these projects
To join the working group or learn more about this initiative, please contact SCB.